Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks
estrogen and progesterone receptors and does not overexpress the human epidermal …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Introduction Triple negative breast cancer (TNBC) is an area of high unmet medical need in
terms of new effective treatment strategies. Although breast cancer is traditionally …

Introduction Triple-negative breast cancer (TNBC) is a breast cancer subtype characterized
by poorer prognosis. Despite that TNBC can display immunogenic features, anti-PD (L) 1 …

Triple-negative breast cancer (TNBC) is an aggressive subtype of mammary carcinoma. A
subset of TNBC is immune activated, suggesting that immunotherapy may be a viable …

Simple Summary Triple-negative breast cancer (TNBC) is the most aggressive breast cancer
subtype accounting for approximately 10–20% of all cases. Due to a lack of actionable …

Breast cancer can be classified based on the expression or lack of expression of protein
receptors including estrogen receptor (ER), progesterone receptor (PR) and human …

Context: Triple negative breast cancers (TNBC) constitute about 15% of breast neoplasms.
In contrast to estrogen receptor (ER) or human epidermal growth factor receptor (HER2) …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It …